304 related articles for article (PubMed ID: 31295152)
1. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Kelley RK; Gane E; Assenat E; Siebler J; Galle PR; Merle P; Hourmand IO; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Faivre S; Benhadji KA; Giannelli G
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00056. PubMed ID: 31295152
[TBL] [Abstract][Full Text] [Related]
2. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
Faivre S; Santoro A; Kelley RK; Gane E; Costentin CE; Gueorguieva I; Smith C; Cleverly A; Lahn MM; Raymond E; Benhadji KA; Giannelli G
Liver Int; 2019 Aug; 39(8):1468-1477. PubMed ID: 30963691
[TBL] [Abstract][Full Text] [Related]
3. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
Giannelli G; Santoro A; Kelley RK; Gane E; Paradis V; Cleverly A; Smith C; Estrem ST; Man M; Wang S; Lahn MM; Raymond E; Benhadji KA; Faivre S
PLoS One; 2020; 15(3):e0222259. PubMed ID: 32210440
[TBL] [Abstract][Full Text] [Related]
5. A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
Ikeda M; Morimoto M; Tajimi M; Inoue K; Benhadji KA; Lahn MMF; Sakai D
Invest New Drugs; 2019 Feb; 37(1):118-126. PubMed ID: 29995286
[TBL] [Abstract][Full Text] [Related]
6. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
Fujiwara Y; Nokihara H; Yamada Y; Yamamoto N; Sunami K; Utsumi H; Asou H; TakahashI O; Ogasawara K; Gueorguieva I; Tamura T
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1143-52. PubMed ID: 26526984
[TBL] [Abstract][Full Text] [Related]
8. Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Serova M; Tijeras-Raballand A; Dos Santos C; Albuquerque M; Paradis V; Neuzillet C; Benhadji KA; Raymond E; Faivre S; de Gramont A
Oncotarget; 2015 Aug; 6(25):21614-27. PubMed ID: 26057634
[TBL] [Abstract][Full Text] [Related]
9. NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC.
Cao Y; Agarwal R; Dituri F; Lupo L; Trerotoli P; Mancarella S; Winter P; Giannelli G
Cell Death Dis; 2017 Feb; 8(2):e2634. PubMed ID: 28230858
[TBL] [Abstract][Full Text] [Related]
10. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
Melisi D; Oh DY; Hollebecque A; Calvo E; Varghese A; Borazanci E; Macarulla T; Merz V; Zecchetto C; Zhao Y; Gueorguieva I; Man M; Gandhi L; Estrem ST; Benhadji KA; Lanasa MC; Avsar E; Guba SC; Garcia-Carbonero R
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688022
[TBL] [Abstract][Full Text] [Related]
11. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Capper D; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Lahn MM; Wick W
Neuro Oncol; 2016 Aug; 18(8):1146-56. PubMed ID: 26902851
[TBL] [Abstract][Full Text] [Related]
12. Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression.
Rani B; Malfettone A; Dituri F; Soukupova J; Lupo L; Mancarella S; Fabregat I; Giannelli G
Cell Death Dis; 2018 Mar; 9(3):373. PubMed ID: 29515105
[TBL] [Abstract][Full Text] [Related]
13. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
Liu X; Yu M; Chen Y; Zhang J
Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307
[TBL] [Abstract][Full Text] [Related]
14. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Wick A; Desjardins A; Suarez C; Forsyth P; Gueorguieva I; Burkholder T; Cleverly AL; Estrem ST; Wang S; Lahn MM; Guba SC; Capper D; Rodon J
Invest New Drugs; 2020 Oct; 38(5):1570-1579. PubMed ID: 32140889
[TBL] [Abstract][Full Text] [Related]
15. High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.
Lin TH; Shao YY; Chan SY; Huang CY; Hsu CH; Cheng AL
Clin Cancer Res; 2015 Aug; 21(16):3678-84. PubMed ID: 25977342
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Rodón J; Carducci M; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly A; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
Invest New Drugs; 2015 Apr; 33(2):357-70. PubMed ID: 25529192
[TBL] [Abstract][Full Text] [Related]
17. Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model.
Hammad S; Cavalcanti E; Werle J; Caruso ML; Dropmann A; Ignazzi A; Ebert MP; Dooley S; Giannelli G
Arch Toxicol; 2018 Jul; 92(7):2297-2309. PubMed ID: 29808285
[TBL] [Abstract][Full Text] [Related]
18. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Melisi D; Garcia-Carbonero R; Macarulla T; Pezet D; Deplanque G; Fuchs M; Trojan J; Oettle H; Kozloff M; Cleverly A; Smith C; Estrem ST; Gueorguieva I; Lahn MMF; Blunt A; Benhadji KA; Tabernero J
Br J Cancer; 2018 Nov; 119(10):1208-1214. PubMed ID: 30318515
[TBL] [Abstract][Full Text] [Related]
19. Disposition and metabolism of [
Cassidy KC; Gueorguieva I; Miles C; Rehmel J; Yi P; Ehlhardt WJ
Xenobiotica; 2018 Apr; 48(4):382-399. PubMed ID: 28436712
[TBL] [Abstract][Full Text] [Related]
20. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Capper D; von Deimling A; Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Estrem ST; Lahn MM; Wick W
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
